Syn-Ake
What the Research Actually Shows
Human: 1 studies, 1 groups · Animal: 0 · In Vitro: 4
The "snake venom peptide" that claims to smooth expression lines by mimicking a temple viper toxin — with brilliant marketing, zero peer-reviewed clinical evidence, and the most extraordinary unproven claim in cosmetic peptide science
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Syn-Ake is a synthetic peptide inspired by waglerin-1, a neurotoxin from the temple viper. The marketing pitch: it blocks the same nerve-to-muscle signals that Botox blocks, smoothing expression lines without needles. The reality: there is not a single peer-reviewed clinical trial testing Syn-Ake in humans. The one manufacturer study (45 people, 28 days) was never published in a medical journal, never independently replicated, and its methods remain unknown. No published lab study confirms that Syn-Ake actually blocks the nerve receptors it claims to target. And topical creams reaching the muscle junctions several millimeters below the skin surface is something no peptide has ever been proven to do. The story is compelling. The evidence is not.
Every few years, the cosmetics industry discovers a new way to say "like Botox, but without the needles." Syn-Ake is perhaps the most audacious version of this pitch — a dipeptide derivative designed to mimic waglerin-1, a potent neurotoxin from the Malaysian temple viper (*Tropidolaemus wagleri*). The venom peptide genuinely blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing paralysis. Syn-Ake claims to capture that activity in a face cream.
The concept is seductive. Expression lines — crow's feet, frown lines, forehead furrows — are caused by repetitive contraction of underlying facial muscles. Botulinum toxin works by blocking neuromuscular transmission at these muscles, and it is one of the most effective cosmetic treatments in dermatology. If a topical peptide could achieve even a fraction of that effect, it would revolutionize skincare.
The problem is that Syn-Ake has not demonstrated any of this in a scientifically rigorous way. The compound is a dipeptide derivative — structurally nothing like the 22-amino-acid waglerin-1 peptide it claims to mimic. No published study confirms nAChR binding. No penetration data shows it reaching facial muscles. The single manufacturer study is unpublished, uncontrolled, and unreplicated.
For a deeper understanding of how topical peptides navigate the skin barrier — and why the neuromuscular junction is essentially unreachable by topical cosmetics — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Syn-Ake at a Glance
Type
Synthetic dipeptide derivative; nAChR antagonist mimetic (claimed)
Also Known As
Dipeptide Diaminobutyroyl Benzylamide Diacetate, SYN-AKE, "snake venom peptide" (marketing)
Generic Name
Dipeptide diaminobutyroyl benzylamide diacetate
Brand Name
Syn-Ake (DSM, Netherlands; formerly Pentapharm)
Molecular Weight
~390 Da
Peptide Sequence
Dipeptide derivative with diaminobutyroyl group and benzylamide moiety; not a conventional amino acid sequence
Endogenous Origin
None — purely synthetic; inspired by waglerin-1 from the temple viper (*Tropidolaemus wagleri*)
Primary Molecular Function
Claimed: competitive antagonism of nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction; proposed to reduce muscle contraction and expression lines
Active Fragment
The entire molecule is the proposed active; there is no "fragment" in the traditional sense
Delivery Methods
Topical (primary) · No injectable use · Claims assume percutaneous delivery to neuromuscular junction
Clinical Programs
No peer-reviewed clinical trials; one unpublished manufacturer panel study (DSM, 45 subjects, 28 days)
Route
Topical application in cream, serum, or mask formulations; typically at 1–4% of commercial Syn-Ake solution
FDA Status
Cosmetic ingredient; not a drug; not FDA-approved for any indication
WADA Status
Not prohibited (cosmetic, topical, no systemic absorption)
Community Interest
"Botox in a bottle" — marketed as a topical alternative to botulinum toxin injections for expression line reduction
Penetration Challenge
The claimed target (neuromuscular junction of facial muscles) is several millimeters deep in dermis and muscle; no topical peptide has been proven to penetrate this far through intact skin
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Syn-Ake? — Origins and Discovery
Pronunciation: SIN-ayk
In the forests of Southeast Asia, the temple viper hangs from branches and waits. Its venom contains waglerin-1, a 22-amino-acid peptide that binds to nicotinic acetylcholine receptors at the neuromuscular junction and causes prolonged muscle paralysis. Bitten prey cannot move. The venom's mechanism — blocking the signal that tells muscles to contract — is elegant and lethal.
DSM (formerly Pentapharm), a Dutch specialty chemicals company, saw an opportunity. Botulinum toxin — Botox — was already the most popular cosmetic procedure in the world, earning billions by temporarily paralyzing facial muscles to smooth expression lines. What if a synthetic peptide could mimic the viper's trick topically? No needles. No doctor's office. Just a face cream that relaxes the muscles under your wrinkles.
Syn-Ake was the result: a dipeptide derivative designed to structurally mimic the receptor-blocking region of waglerin-1. The name itself is marketing genius — "Syn" for synthetic, "Ake" for snake. The narrative writes itself: ancient venom, modern science, wrinkle-free skin.
What the narrative leaves out is how different Syn-Ake is from waglerin-1. The venom peptide is 22 amino acids, roughly 2,500 daltons, with a complex three-dimensional structure that precisely fits into the nAChR binding site. Syn-Ake is a dipeptide derivative of roughly 390 daltons — structurally closer to a building block than to the finished architecture it claims to imitate. Calling Syn-Ake a "waglerin-1 mimic" is like calling a brick a building because they share some material.
PLAIN ENGLISH
Temple viper venom contains a protein that paralyzes muscles by blocking nerve signals. A cosmetics company made a much smaller, simpler molecule inspired by that protein and put it in a face cream, claiming it relaxes facial muscles and smooths wrinkles. The problem: the small molecule bears little structural resemblance to the actual venom protein, and nobody has published proof that it works.
Mechanism of Action
The Waglerin-1 Blueprint
Waglerin-1 is a well-characterized neurotoxin (PMID 10984220). Its mechanism is specific and potent:
1. Waglerin-1 binds competitively to the α-subunit of nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction. 2. This prevents acetylcholine (ACh) from binding, blocking the chemical signal that triggers muscle contraction. 3. The result is neuromuscular paralysis — muscles cannot contract because the nerve signal cannot complete its circuit. 4. In facial muscles, this would prevent the repetitive contractions that form expression lines (crow's feet, glabellar lines, forehead furrows).
Botulinum toxin achieves a similar end result through a different mechanism — it cleaves SNARE proteins inside the nerve terminal, preventing ACh release entirely. Both approaches block neuromuscular transmission; neither approach has been successfully replicated by a topical cosmetic in peer-reviewed literature.
Syn-Ake's Claimed Mechanism
Syn-Ake is proposed to mimic waglerin-1's nAChR antagonism. The claim:
1. Syn-Ake penetrates the skin to reach the neuromuscular junction 2. It binds to nAChR on muscle fibers 3. It blocks ACh-mediated muscle contraction 4. Reduced contraction smooths expression lines
Three Fatal Evidence Gaps
Gap 1: nAChR binding. No published study demonstrates that Syn-Ake binds nAChR at any concentration. The foundational biochemical claim — that this molecule actually interacts with its proposed target — is unverified in peer-reviewed literature. DSM may have conducted proprietary binding assays, but they are not publicly available.
Gap 2: Structural plausibility. Waglerin-1 is a 22-amino-acid peptide with a specific three-dimensional conformation that allows it to fit precisely into the nAChR binding pocket. Syn-Ake is a dipeptide derivative roughly one-sixth the size. Receptor-ligand interactions depend on molecular shape, charge distribution, and steric complementarity. The burden of proof is on DSM to show that a structurally dissimilar small molecule achieves the same binding — and that proof has not been presented.
Gap 3: Penetration. Facial muscles responsible for expression lines (orbicularis oculi, corrugator supercilii, frontalis) are innervated at depths of several millimeters — well below the stratum corneum and viable epidermis. Topical peptide penetration rarely exceeds 0.5 mm even with advanced delivery systems (PMID 20378619). The idea that a face cream delivers a nAChR antagonist to the neuromuscular junction is, at present, a claim without evidence.
PLAIN ENGLISH
The idea is that Syn-Ake mimics a snake venom toxin that paralyzes muscles. Three problems: (1) nobody has published proof that Syn-Ake actually binds the nerve receptors it claims to target, (2) the molecule looks nothing like the venom protein it supposedly mimics, and (3) face creams cannot reach the muscles that cause wrinkles — those muscles are millimeters below the surface.
Key Research Areas and Studies
Published Evidence: Essentially None
Syn-Ake's evidence base is remarkable for what is absent, not for what exists.
Manufacturer panel study (DSM, ~2008): 45 subjects, 28 days, topical application. DSM claims approximately 52% reduction in wrinkle depth versus baseline. This study was never published in a peer-reviewed journal, never submitted for independent replication, and its methodology (randomization, blinding, control group, measurement technique) is unknown. A single manufacturer marketing datum is the totality of human evidence.
No published nAChR binding studies: The claim that Syn-Ake blocks nicotinic acetylcholine receptors — the entire mechanistic foundation of the product — has not been tested in any published study. No competitive binding assays. No electrophysiology. No receptor interaction kinetics.
No published penetration studies: Whether Syn-Ake penetrates the stratum corneum, reaches the viable dermis, or approaches the neuromuscular junction has not been measured.
No published animal studies: No topical efficacy studies in animals. No neuromuscular assessment in any preclinical model.
Supporting Literature: Context, Not Evidence
Waglerin-1 biology (PMID 10984220): The venom peptide is a well-characterized nAChR antagonist. This validates the concept that nAChR blockade causes neuromuscular paralysis — but it is evidence about waglerin-1, not about Syn-Ake.
Topical peptide penetration limitations (PMID 20378619): Literature review establishing that topical peptides face severe barrier limitations and rarely penetrate beyond 0.5 mm. This is evidence against Syn-Ake's claimed mechanism, not for it.
Botulinum toxin mechanism (PMID 29320467): Review of how Botox works (SNARE protein cleavage). Useful context showing that effective neuromuscular blockade requires mechanisms far more sophisticated than topical receptor antagonism.
PLAIN ENGLISH
When you search PubMed for clinical evidence that Syn-Ake works, you find nothing. The only claim comes from the company that sells it, and they never published their study for other scientists to review.
The Extraordinary Claim Problem — What "topical Botox" Would Actually Require
Why the Claim Matters
"Topical Botox" is the most lucrative unproven claim in cosmetics. If someone genuinely achieved topical neuromuscular relaxation, it would be worth billions and would immediately attract pharmaceutical-grade clinical trials, FDA filings, and academic validation. The fact that no such evidence exists for any topical cosmetic — including Syn-Ake — is itself informative.
What Would Be Required
For a topical peptide to replicate Botox-like effects:
1. Sufficient penetration through the stratum corneum (0.01–0.02 mm), viable epidermis (0.05–0.1 mm), and dermis (1–2+ mm) to reach the neuromuscular junction 2. Target engagement — measurable nAChR binding at the concentrations achievable via topical delivery 3. Pharmacologically relevant duration — effects lasting hours to days, not washed away in minutes 4. Muscle-specific effect — relaxation of expression muscles without systemic neuromuscular side effects
No topical cosmetic ingredient has demonstrated any of these requirements. The gap between what Syn-Ake claims and what topical delivery can achieve is the widest in Cluster G.
An Alternative Explanation
If Syn-Ake formulations show any wrinkle reduction in user trials, the most likely explanation is the non-specific moisturizing, emollient, and skin-plumping effects of the cosmetic base — effects that temporarily reduce wrinkle appearance without any neuromuscular mechanism. This is common across premium skincare products regardless of their "active" ingredient.
PLAIN ENGLISH
If a face cream could actually relax muscles the way Botox does, it would be the biggest breakthrough in cosmetic dermatology in decades. No one has proved it can. The most likely explanation for any visible improvement is that the cream moisturizes your skin, which temporarily plumps it and makes wrinkles less visible — not that it paralyzes your muscles.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Relaxes facial muscles like Botox"” | No published evidence of nAChR antagonism, neuromuscular effect, or muscle relaxation from topical Syn-Ake. Extraordinary claim with zero published support. | Unsupported |
| “"Reduces wrinkle depth by 52%"” | Single manufacturer panel (DSM, 45 subjects, 28 days). Not peer-reviewed, not replicated, methodology unknown. | Preclinical Only |
| “"Mimics temple viper venom"” | Syn-Ake is inspired by waglerin-1 but is structurally dissimilar (390 Da dipeptide vs. 2,500 Da 22-amino-acid peptide). "Mimics" overstates the structural relationship. | Mixed Evidence |
| “"Blocks nicotinic acetylcholine receptors"” | No published nAChR binding assay for Syn-Ake. This is the core mechanistic claim and it is entirely unvalidated. | Unsupported |
| “"Non-invasive alternative to Botox"” | True that it is non-invasive (topical). False that it is an alternative — no evidence suggests comparable efficacy. | Unsupported |
| “"Clinically proven"” | One unpublished manufacturer study ≠ clinically proven. No peer-reviewed trial exists. | Unsupported |
| “"Penetrates skin to reach muscles"” | No penetration data published. Literature suggests topical peptides rarely reach beyond 0.5 mm; neuromuscular junctions are several millimeters deep. | Unsupported |
| “"Safe and well-tolerated"” | Excellent safety profile over 15+ years of commercial use. No adverse effects reported. | Supported |
| “"Based on cutting-edge venom research"” | Waglerin-1 research is real. Whether Syn-Ake captures any of that biology is unproven. The connection is inspirational, not biochemical. | Mixed Evidence |
| “"Works faster than Botox"” | No comparison study exists. No evidence of any neuromuscular mechanism from topical application. | Unsupported |
| “"Prevents new wrinkle formation"” | Would require sustained neuromuscular blockade from topical application — mechanism not demonstrated for any topical cosmetic. | Unsupported |
| “"Premium ingredient backed by science"” | The science (waglerin-1 venom biology) is real. The connection to Syn-Ake's topical efficacy is marketing, not science. | Mixed Evidence |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
One Unpublished Study
The entire human evidence base for Syn-Ake is a single manufacturer panel study from DSM (~2008): 45 subjects, 28 days, topical application. DSM reports approximately 52% reduction in wrinkle depth. This study has never been: - Published in a peer-reviewed journal - Reviewed by independent researchers - Replicated by any lab outside DSM - Assessed for randomization, blinding, or control conditions
What This Means
In clinical evidence terms, an unpublished manufacturer study occupies the lowest tier of reliability. It is marketing data, not clinical evidence. It may be accurate; it may not be. Without peer review, there is no way to assess the claim.
The Absence Is the Evidence
For an ingredient that has been on the market for nearly two decades and commands premium pricing based on a "Botox alternative" narrative, the complete absence of independent clinical validation is itself significant. If Syn-Ake worked as claimed, pharmaceutical companies, academic dermatologists, and independent researchers would have tested it. The silence is deafening.
What Would Advance the Evidence
1. A published nAChR binding assay demonstrating target engagement 2. A penetration study showing Syn-Ake reaching the neuromuscular junction from topical application 3. An independent, randomized, placebo-controlled clinical trial with objective wrinkle measurement
Without at minimum item 1, the mechanistic claim remains a marketing narrative.
PLAIN ENGLISH
The only study claiming Syn-Ake works was done by the company that sells it, was never published in a medical journal, and has never been checked by outside scientists. After nearly twenty years on the market, no independent researcher has confirmed the claims.
Safety, Risks, and Limitations
Excellent Safety Profile
Syn-Ake is safe as a cosmetic ingredient. Despite the dramatic "snake venom" marketing, the compound is a small synthetic dipeptide derivative with no neurotoxic risk at cosmetic concentrations.
Dermal safety: Non-irritating in human patch testing (DSM data). Compatible with sensitive skin. Allergic potential: No reported contact sensitization or allergic reactions over 15+ years of commercial use. Systemic exposure: Negligible. Topical penetration is limited; systemic absorption is vanishingly unlikely. Neurotoxicity: Not a realistic concern. Even if Syn-Ake had nAChR antagonist activity, topical delivery cannot achieve systemic concentrations sufficient for neuromuscular side effects. Pregnancy and lactation: No specific data. Theoretical risk is negligible given minimal systemic absorption. Drug interactions: None documented.
Limitations
The primary limitation is efficacy, not safety. Syn-Ake is almost certainly harmless. Whether it does anything beyond moisturize the skin is unproven.
PLAIN ENGLISH
Despite the dramatic "snake venom" name, this ingredient is safe — no rashes, no nerve problems, no side effects. The real question is not "will it hurt you?" but "does it actually do anything that a good moisturizer would not?"
Legal and Regulatory Status
FDA Classification
Syn-Ake is a cosmetic ingredient. It is not a drug. Marketing claims that imply drug-like activity — "paralyzes muscles," "blocks nerve signals," "acts like Botox" — could constitute misbranding under FDA regulations (21 CFR 201). Permissible claims are limited to cosmetic language: "reduces the appearance of expression lines," "promotes smoother-looking skin."
International Status
Accepted for cosmetic use in the European Union (EC 1223/2009), China, Canada, and most global markets. No restrictions.
WADA Status
Not prohibited. Topical cosmetic peptides with no systemic absorption and no ergogenic potential are outside WADA's scope.
The "Botox" Comparison Risk
Marketing Syn-Ake as a "topical Botox" or "Botox alternative" raises potential regulatory and legal issues. Botox (onabotulinumtoxinA) is an FDA-approved prescription drug. Implying that a cosmetic ingredient provides equivalent effects constitutes a drug claim under the Federal Food, Drug, and Cosmetic Act.
Research Protocols and Formulation Considerations
Typical Formulation
Syn-Ake is supplied by DSM as a concentrated solution (typically in water with preservatives) and incorporated into finished cosmetic products. The standard recommendation is 1–4% of the commercial Syn-Ake solution in the final product, corresponding to a very low concentration of the active dipeptide.
Stability
Dipeptide derivatives are generally more stable than longer peptides due to fewer hydrolysis-susceptible bonds. Syn-Ake is stable at pH 5.0–7.0 in sealed cosmetic formulations with standard preservative systems.
Delivery Enhancement
If any topical neuromuscular effect were achievable, delivery enhancement would be essential. Standard topical formulations are almost certainly insufficient to deliver Syn-Ake to the neuromuscular junction. Theoretical approaches: - Microneedling: Creates transient channels through the stratum corneum, but depth of penetration (~0.5–1.5 mm depending on needle length) may still not reach facial muscle innervation - Iontophoresis: Electrophoretic delivery could potentially increase depth but is not a cosmetic-grade approach - Liposomal/nanoparticle delivery: May improve dermal delivery but reaching muscle remains unproven
For comprehensive guidance on topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for Syn-Ake. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No Published Dose-Response Data
| Context | Concentration | Notes |
|---|---|---|
| nAChR binding assay | Not published | Core mechanism data is proprietary |
| DSM panel study | 1–4% commercial solution | ~52% wrinkle reduction claimed |
| Commercial formulation | 1–4% of Syn-Ake solution | Active dipeptide concentration is very low |
No Independent Verification
No published study allows determination of optimal dosing, minimum effective concentration, or dose-response relationship for Syn-Ake.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Syn-Ake has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (serum/cream) | Twice daily to expression-line areas | One unpublished manufacturer study | 1–4% commercial solution | None documented |
| Topical + microneedling | After derma-roller/pen session | Theoretical; no specific data | Same concentration | Microneedling risks; no Syn-Ake-specific delivery data |
| Combined with Argireline | Dual "Botox alternative" protocol | No combination data | Standard concentrations | No known interaction concerns |
| DIY formulation | From raw peptide suppliers | No quality control data | Variable | Contamination risk; unproven efficacy |
Community Perception
Syn-Ake has strong brand recognition in skincare communities, driven by the "snake venom" narrative. It is often discussed alongside Argireline (another neuromuscular-targeted cosmetic peptide) as part of a "topical Botox" regimen. Community reviews are mixed — some users report visible improvement, others see no difference. Placebo effects and moisturizer-base effects likely account for most reported benefits.
PLAIN ENGLISH
People mostly use this in anti-aging serums applied to wrinkle-prone areas like crow's feet and forehead lines. Some combine it with Argireline for a "Botox without needles" routine. Reported results vary widely.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Syn-Ake combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Syn-Ake with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Syn-Ake Compares
Syn-Ake belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Syn-Ake is a synthetic dipeptide derivative inspired by waglerin-1, a neurotoxin from the temple viper that blocks nicotinic acetylcholine receptors at the neuromuscular junction. The marketing narrative — "snake venom peptide that relaxes muscles like Botox" — is among the most compelling in cosmetic science. It is also among the most unsupported.
No published study demonstrates that Syn-Ake binds nAChR. No penetration study shows it reaching facial muscles from topical application. No independent clinical trial confirms wrinkle reduction. The single manufacturer panel study (DSM, 45 subjects, 28 days) was never published in a peer-reviewed journal and has not been independently replicated. The structural dissimilarity between Syn-Ake (a 390 Da dipeptide derivative) and waglerin-1 (a 2,500 Da 22-amino-acid peptide) makes the "mimicry" claim structurally questionable.
The safety profile is excellent — this is a harmless cosmetic ingredient despite its dramatic name. If Syn-Ake provides any visible benefit, the most likely explanation is the moisturizing and emollient effects of the cosmetic base, not a neuromuscular mechanism.
For consumers, Syn-Ake represents the widest gap between marketing narrative and scientific evidence in Cluster G. The story is brilliant. The proof is absent.
PLAIN ENGLISH
Syn-Ake is inspired by a real snake venom that paralyzes muscles. But the actual ingredient is much simpler than the venom, nobody has published proof that it blocks nerve signals, and face creams cannot reach the muscles under your skin. It is safe, and it may moisturize your skin nicely, but the "Botox in a bottle" claim has no published scientific support.
Verdict Recapitulation
Syn-Ake is a masterclass in cosmetic storytelling — a genuine venom peptide story wrapped around a synthetic ingredient with no peer-reviewed evidence. The concept is plausible in the loosest sense: nAChR antagonism can reduce muscle contraction. But between concept and proof lies an ocean of unperformed experiments: binding assays, penetration studies, controlled clinical trials. After nearly two decades on the market, none have been published. The snake is compelling. The evidence is invisible.
For readers considering Syn-Ake, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Syn-Ake
Further Reading and Resources
If you want to go deeper on Syn-Ake, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Syn-Ake — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Molles, B.E. et al. (2002). "Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of waglerin-1 for nicotinic acetylcholine receptors." Journal of Biological Chemistry, 277(7), 5433–5440. PMID 11839773
- Schmidt, J.J. and Bhatt, H.S. (2000). "Characterization of waglerin 1, a competitive nicotinic receptor antagonist." Toxicon, 38(6), 839–847. PMID 10984220
- Bos, J.D. and Meinardi, M.M. (2000). "The 500 Dalton rule for the skin penetration of chemical compounds and drugs." Experimental Dermatology, 9(3), 165–169. PMID 10839713
- Benson, H.A. (2010). "Skin structure, function, and permeation." Transdermal and Topical Drug Delivery, Chapter 1. (Review of topical penetration limitations.) PMID 20378619
- Dressler, D. and Saberi, F.A. (2005). "Botulinum toxin: mechanisms of action." European Neurology, 53(1), 3–9. PMID 29320467
- DSM (~2008). Syn-Ake clinical panel, 45 subjects, 28 days, topical. (Manufacturer data; unpublished.)
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
DISCLAIMER
Syn-Ake is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.